Intercell, a developer of vaccines for the prevention and treatment of infectious diseases, has named Staph Leavenworth Bakali as new chief business officer, effective 1 October 2010.
Subscribe to our email newsletter
Bakali will be responsible for Marketing and Sales, Corporate and Business Development, and Alliance Management of the company.
Bakali will also play a key role with the other management board members in helping drive forward the company’s strategy.
Most recently, Bakali worked as the CEO of Genocea Biosciences, a Boston- based biotech vaccine company.
Intercell CEO Gerd Zettlmeissl said that Staph has an outstanding track record in the vaccines industry and has made major contributions to the success of some key vaccines businesses globally.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.